Please login first

Biology Webinar | Infection-Associated Liver Diseases

14 Dec 2021, 15:00 (CET)

Liver Disease, Steatosis, HIV, HCV, HBV, PNPLA3, New Therapeutic Targets, Longacting Nucleoside
Bookmark event Remove event from bookmarks
Add this event to bookmarks
Event Registration Contact Us

Welcome from the Chairs

2nd Biology Webinar

Infection-Associated Liver Diseases

Viral hepatitis is a substantial part of non-alcoholic liver diseases. Hepatotropic viruses may serve as cytotoxic and non-cytotoxic agents driving the disease progression, which potentially may lead to chronic liver injury. Co-infections with other hepatotropic viruses increase the pathogenesis of viral hepatitis and the progression to end-stage liver diseases. Non-alcoholic steatohepatitis is one of the common features accompanying viral hepatitis development but the mechanisms behind this are not quite clear. In this Webinar, we will focus on some aspects of liver-associated HIV-infection as well as on potentiation of HIV with HCV-infection. In addition, since chronic hepatitis B (CHB) is still considered as an uncurable infection, we will overview new therapeutic targets for CHB treatment and the application of long-acting nucleoside reverse transcriptase inhibitors as a potential medication for this infection.

Date: 14 December 2021

Time: 3:00pm CET | 9:00am EST | 10:00pm CST Asia

Webinar ID: 890 0786 5051

Webinar Secretariat:


Department of Internal Medicine, University of Nebraska Medical Center, USA

Associate Professor, Internal Medicine, Gastroenterology & Hepatology. Her areas of Interest include: Role of inflammation, innate immunity, apoptosis, proteasome dysfunctions and extracellular vesicles in the mechanisms of liver disease development; alcohol-induced liver injury; HIV-triggered liver injury; HCV, HBV and HIV-co-infections; second hits (co-infections, alcohol) in potentiation of HIV-induced liver and fibrosis progression.

Invited Speakers

Division of Digestive Diseases, University of Cincinnati, USA

MD, Professor Division Chief; Robert and Helen Gould Endowed Professorship. His areas of interests include: Viral Hepatitis - Molecular Heterogeneity, Diagnosis and Treatment, Liver Disease in HIV Infected Patients, Drug Hepatotoxicity..

Department of Internal Medicine, Virginia Commonwealth University, Richmond, USA

Dr. Sterling received his BS in Chemistry and Natural Science from Muhlenberg College in Allentown Pa in 1982, a MA in Biochemistry from the University of Texas in Austin in 1984, and a MD from Jefferson Medical College in Philadelphia in 1988. After completing an internship and residency in Internal Medicine at Virginia Commonwealth University/Medical College of Virginia in, he went on to complete a fellowship in Gastroenterology, Hepatology, and Nutrition at VCU which include specialized training in Transplant Hepatology in 1994. He is currently a VCU Hepatology Professor of Medicine and Section Chief of Hepatology and Medical Director of Viral Hepatitis at VCUHS and is the Transplant Hepatology Fellowship Director. His research interest is in HIV-liver disease which is supported by several NIH grants. He has been an NIH-funded investigator for many years. He has published over 190 papers and serves on several prominent committees of national associations such as the AGA, AASLD, and ACG and study sections of the NIH. He is currently vice chair of the Liver-Biliary Council of the AGA, a member of the Gastroenterology Board of the American Board of Internal Medicine, and has served as the ACG Governor for Virginia. He has won numerous awards for teaching and was voted “Top Doc” in 2012 and 2013 Richmond magazine.

Institute of Hepatology, King’s College London, London, UK

Dr Sandra Phillips is currently a Senior Scientist in the Liver Immunology group led by Dr Shilpa Chokshi at the Institute of Hepatology, and an honorary Lecturer at King’s College London. She received her PhD in Hepatology from University College London in 2011. Her research focuses on understanding the host-virus interactions associated with the pathogenesis of Hepatitis B infection (HBV) to identify new immune and molecular therapeutic strategies for chronic HBV and liver disease. Her projects involve the use of in-vitro and ex-vivo human liver models of HBV infection at containment level 3. She is also involved in the immune monitoring of national and international clinical trials for HBV.

Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, USA

Professor; Co-Director for Translational Mouse Model Core Facility; Co-Director for PAMM 912/PHAR902: Human-Specific Disease Modeling in Mice. Her areas of interests include: HIV-1 pathogenesis, therapeutics and vaccines, humanized mice for translational research, stem cell transplantation. The long range goals are to development small animal models to study the pathogenesis of human-specific viral co-infection - HIV-1 and HCV/HBV.

Webinar Content

To view this content, you need to be registered and logged in to Sciforum platform.



Time in CET

Chair Prof. Dr. Natalia Osna

Chair Introduction

3:00 - 3:10 pm

Prof. Dr. Kenneth E. Sherman

PNPLA3: Prevalence and Associations with Liver Disease in Persons Living with HIV

3:10 - 3:25 pm

Q&A Session

3:25 - 3:30 pm

Prof. Dr. Richard K. Sterling

Impact of Steatosis on SVR in HCV-HIV

3:30 - 3:45 pm

Q&A Session

3:45 - 3:50 pm

Dr. Sandra Phillips

New Therapeutic Targets for Chronic HBV Infection

3:50 - 4:05 pm

Q&A Session

4:05- 4:10 pm

Prof. Dr. Larisa Poluektova

Long-Acting Nucleoside Reverse Transcriptase Inhibitors: Potentials for Chronic Hepatitis B Treatment

4:10 - 4:25 pm

Q&A Session

4:25 - 4:30 pm

Closing of Webinar

Chair Prof. Dr. Natalia Osna

4:30 - 4:40 pm

Relevant SI

Non-Alcoholic Liver Injury
Guest Editors: Prof. Dr. Natalia Osna, Prof. Dr. Valentina Medici & Prof. Dr. Kusum K. Kharbanda
Deadline for manuscript submissions: closed (31 March 2021)

Sponsors and Partners